Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

21. Osteoporosis

Osteoporosis Osteoporosis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Osteoporosis Last reviewed: August 2018 Last updated: March 2018 Summary Asymptomatic until fracture occurs. Diagnosis based on history of prior fragility fracture or low bone mineral density (BMD), which is defined as a T-score ≤-2.5. Screening is based on individual risk factors, including female gender, maternal history of fragility fracture (...) /osteoporosis, older age, low body mass index (<20 to 25 kg/m^2), body weight <58 kg, weight loss of >10% of body weight, androgen deprivation treatment (in males), aromatase inhibitor treatment (in females), corticosteroid use, tobacco use, and kidney stone disease. Fall prevention is first-line therapy. Bisphosphonates are first-line pharmacological therapy for postmenopausal women and men. In postmenopausal women, oestrogen is considered only for those at high risk for whom non-oestrogen medicines

BMJ Best Practice2018

22. Cone Beam Computed Tomography Can be Used as an Auxiliary Diagnostic Tool for Osteoporosis

Cone Beam Computed Tomography Can be Used as an Auxiliary Diagnostic Tool for Osteoporosis UTCAT3302, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Cone Beam Computed Tomography Can be Used as an Auxiliary Diagnostic Tool for Osteoporosis Clinical Question Can cone beam computed tomography be considered a helpful tool in predicting osteoporosis? Clinical Bottom Line Cone beam computed tomography imaging (...) is a promising technique to predict osteoporosis. For patients who have osteoporosis, CBCT radiodensity can be a predictor of low bone mineral density (BMD). Dentists can use this as a tool to help in early diagnosis and referral of the patient to a physician to manage the case before deterioration. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Guerra/2017 6 studies, 220 patients Systematic review

UTHSCSA Dental School CAT Library2017

23. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. BACKGROUND: No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis. METHODS: In this double-blind, double-dummy trial, we enrolled post-menopausal women with (...) compared with 61 (9·8%) of 680 in the risedronate group (hazard ratio 0·48, 95% CI 0·32-0·74; p=0·0009). Non-vertebral fragility fractures occurred in 25 (4·0%) patients in the teriparatide group and 38 (6·1%) in the risedronate group (hazard ratio 0·66; 95% CI 0·39-1·10; p=0·10). INTERPRETATION: Among post-menopausal women with severe osteoporosis, the risk of new vertebral and clinical fractures is significantly lower in patients receiving teriparatide than in those receiving risedronate. FUNDING

Lancet2017

24. Leveraging Scarce Resources With Bone Health TeleECHO to Improve the Care of Osteoporosis

Leveraging Scarce Resources With Bone Health TeleECHO to Improve the Care of Osteoporosis 29264466 2018 11 13 2472-1972 1 12 2017 Dec 01 Journal of the Endocrine Society J Endocr Soc Leveraging Scarce Resources With Bone Health TeleECHO to Improve the Care of Osteoporosis. 1428-1434 10.1210/js.2017-00361 Osteoporosis is a common condition with serious consequences because of fractures. Despite availability of treatments to reduce fracture risk, there is a large osteoporosis treatment gap (...) health care professionals in the United States and several other countries, with 221 attending at least 1 online clinic and typically 35 to 40 attendees at each session at the end of the reported period. Assessment of self-confidence in 20 domains of osteoporosis care showed substantial improvement with the ECHO intervention ( P = 0.005). Bone Health TeleECHO can contribute to mitigating the crisis in osteoporosis care by leveraging scarce resources, providing motivated practitioners with skills

Journal of the Endocrine Society2017 Full Text: Link to full Text with Trip Pro

25. Prevention of osteoporosis in female students based on the Orem self-care model

Prevention of osteoporosis in female students based on the Orem self-care model 29238485 2018 11 13 2008-5842 9 10 2017 Oct Electronic physician Electron Physician Prevention of osteoporosis in female students based on the Orem self-care model. 5465-5471 10.19082/5465 The World Health Organization has introduced osteoporosis as the fourth main enemy of mankind. Self care has served as a new trend in health care. Educational intervention for osteoporosis related preventive self care in female (...) university students using the Orem model. This study is a controlled filed trial, carried out with female students of Islamic Azad University, Shahrekord Branch, Iran, from October 28, 2014 to November 15, 2016. Two-stage random stratified sampling was performed and the data were collected through a validated questionnaire developed by the researcher for osteoporosis preventive self-care based on the Orem model. The intervention group received education about osteoporosis preventive self-care through two

Electronic physician2017 Full Text: Link to full Text with Trip Pro

26. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. Background Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. Methods We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open (...) events were observed more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 patients [1.9%]). During the open-label alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 events and 4 events, respectively) were observed. Conclusions In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment

NEJM2017

27. Bisphosphonates for treating osteoporosis

Bisphosphonates for treating osteoporosis Bisphosphonates for treating Bisphosphonates for treating osteoporosis osteoporosis T echnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Bisphosphonates for treating osteoporosis (TA464) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 25Contents Contents 1 Recommendations 4 2 The technologies 7 3 Committee discussion 9 Nature of the condition 9 Clinical management of the condition 9 Assessing

National Institute for Health and Clinical Excellence - Technology Appraisals2017

28. Osteoporosis.

Osteoporosis. Osteoporosis is a common systemic skeletal disorder resulting in bone fragility and increased fracture risk. However, management of osteoporosis and fracture prevention strategies are often not addressed by primary care clinicians, even in older patients with recent fractures. Evidence-based screening strategies will improve identification of patients who are most likely to benefit from drug treatment to prevent fracture. In addition, careful consideration of when pharmacotherapy

Annals of Internal Medicine2017

29. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis 28585410 2017 06 06 2017 07 27 2151-4658 69 8 2017 Aug Arthritis care & research Arthritis Care Res (Hoboken) 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. 1095-1110 10.1002/acr.23279 To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP). We conducted (...) and vitamin D in adults at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred) in adults at moderate-to-high fracture risk, continuing calcium plus vitamin D but switching from an oral bisphosphonate to another antifracture medication in adults in whom oral bisphosphonate treatment is not appropriate, and continuing oral bisphosphonate treatment or switching to another antifracture medication in adults who complete a planned

EvidenceUpdates2017

30. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. BACKGROUND: Previous bisphosphonate treatment attenuates the bone-forming effect of teriparatide. We compared the effects of 12 months of romosozumab (AMG 785), a sclerostin monoclonal antibody, versus teriparatide on bone mineral density (BMD) in women with postmenopausal osteoporosis transitioning (...) from bisphosphonate therapy. METHODS: This randomised, phase 3, open-label, active-controlled study was done at 46 sites in North America, Latin America, and Europe. We enrolled women (aged ≥55 to ≤90 years) with postmenopausal osteoporosis who had taken an oral bisphosphonate for at least 3 years before screening and alendronate the year before screening; an areal BMD T score of -2·5 or lower at the total hip, femoral neck, or lumbar spine; and a history of fracture. Patients were randomly

Lancet2017

31. Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value

Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value ©Institute for Clinical and Economic Review, 2017 Anabolic Therapies for Osteoporosis in Postmenopausal Women: Effectiveness and Value Evidence Report June 16, 2017 Prepared for Note: When our process began, ICER expected FDA approval of two new anabolic agents for osteoporosis in the first half of 2017. On May 21, 2017, Amgen and UCB issued a press release with topline results from the ARCH trial (...) that include romosozumab. However, we have elected to retain the summary of the romosozumab trial results as well as the newly available summary results of the ARCH trial because they provide important contextual information to frame the larger discussion of the role of anabolic therapies in preventing osteoporotic fractures. ©Institute for Clinical and Economic Review, 2017 Page i Evidence Report – Anabolic Therapies for Osteoporosis ICER Staff and Consultants University of Washington School of Pharmacy

California Technology Assessment Forum2017

32. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis

2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis 28585373 2017 06 06 2017 06 06 2326-5205 2017 Jun 06 Arthritis & rheumatology (Hoboken, N.J.) 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. 10.1002/art.40137 To develop recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP). We conducted a systematic review (...) at low fracture risk, treating with calcium and vitamin D plus an additional osteoporosis medication (oral bisphosphonate preferred) in adults at moderate-to-high fracture risk, continuing calcium plus vitamin D but switching from an oral bisphosphonate to another antifracture medication in adults in whom oral bisphosphonate treatment is not appropriate, and continuing oral bisphosphonate treatment or switching to another antifracture medication in adults who complete a planned oral bisphosphonate

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

33. Nutrition and osteoporosis prevention for the orthopaedic surgeon: A wholefoods approach

Nutrition and osteoporosis prevention for the orthopaedic surgeon: A wholefoods approach 28736622 2018 11 13 2058-5241 2 6 2017 Jun EFORT open reviews EFORT Open Rev Nutrition and osteoporosis prevention for the orthopaedic surgeon: A wholefoods approach. 300-308 10.1302/2058-5241.2.160079 Osteoporosis is a prevalent and debilitating condition with no signs of subsiding. Rising numbers of people consuming nutrient-poor diets coupled with ageing populations and sedentary lifestyles appear (...) to be the main drivers behind this.While the nutrients calcium and vitamin D have received most attention, there is growing evidence that wholefoods and other micronutrients have roles to play in primary and potentially secondary osteoporosis prevention.Until recently, calcium and vitamin D were regarded as the main nutrients essential to bone health but now there are emerging roles for iron, copper and selenium, among others.Fruit and vegetables are still not being eaten in adequate amounts and yet contain

EFORT open reviews2017 Full Text: Link to full Text with Trip Pro

34. Bindex for people with suspected osteoporosis

Bindex for people with suspected osteoporosis Binde Bindex for in x for inv vestigating suspected osteoporosis estigating suspected osteoporosis Medtech innovation briefing Published: 31 May 2017 nice.org.uk/guidance/mib106 pathways Summary Summary The technology technology described in this briefing is Bindex, a portable pulse-echo ultrasound device used to help make decisions on the investigation and treatment of osteoporosis. The inno innovativ vative aspects e aspects are that it is pocket (...) sized and can be connected to and used with any laptop or desktop computer's USB socket. Unlike other quantitative ultrasound that measures sound speed and attenuation in the heel, Bindex makes measurements of the tibia applying thresholds of 90% sensitivity and specificity compared with axial dual-energy X-ray absorptiometry (DXA), to help with decisions on further tests and treatment for osteoporosis. The intended place in ther place in therap apy y would be to use Bindex alongside current

National Institute for Health and Clinical Excellence - Advice2017

35. Abaloparatide (Tymlos) Subcutaneous Injection - osteoporosis in postmenopausal women

Abaloparatide (Tymlos) Subcutaneous Injection - osteoporosis in postmenopausal women Tymlos Subcutaneous Injection U.S. Department of Health and Human Services Search FDA Submit search Tymlos Subcutaneous Injection DUPIXENT Company: Radius Health, Inc. Application No.: 208743 Approval Date: 04/28/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2017

36. In patients with osteoporosis, should subclinical hyperthyroidism be treated?

In patients with osteoporosis, should subclinical hyperthyroidism be treated? In patients with osteoporosis, should subclinical hyperthyroidism be treated? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics In patients with osteoporosis, should subclinical hyperthyroidism be treated? View/ Open Date 2017-04 Format (...) Metadata Abstract In patients with osteoporosis, should subclinical hyperthyroidism be treated? Evidence-based answer: Subclinical hyperthyroidism with thyroid-secreting hormone (TSH) [less than or equal to] 0.45 mIU/L is associated with an increased fracture rate (SOR: A, meta-analysis of cohort studies), but treatment of subclinical hyperthyroidism when TSH is [less than or equal to] 0.2 mIU/L only slightly increases bone mineral density (BMD) (SOR: C, case-control study with disease-oriented

Evidence Based Practice 2017

37. Romosozumab for osteoporosis in men

Romosozumab for osteoporosis in men Romosozumab for osteoporosis in men ‐ NIHR Innovation Observatory ☰ Menu Search Filter by Specialty Filter by Year Romosozumab for osteoporosis in men May 2017 Technology Description: Romosozumab arose from a genetic discovery that revealed the body’s own natural ability to increase bone strength. It is a treatment which aims to block the activity of the protein sclerostin. This diminishes bone breakdown and removal and stimulates bone formation, thereby (...) increasing bone strength. The effectiveness and safety of romosozumab for the treatment of osteoporosis in men has been studied in a phase III clinical trial. The study showed that romosozumab given by injection monthly for a 12 month period significantly increased the formation of new bones, reducing the risk of a fracture. Romosozumab was also found to be safe with no significant adverse effects. Specialty You may also be interested in: Apr 2015 Specialty: Feb 2015 Specialty: Dec 2014 Specialty: Please

NIHR Innovation Observatory2017

38. Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians.

Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update from the American College of Physicians. Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations (...) for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen. Evidence was graded according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians. The target patient population includes men and women with low bone density and osteoporosis. Recommendations Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment

Annals of Internal Medicine2017

39. Teriparatide (Movymia) - osteoporosis

Teriparatide (Movymia) - osteoporosis 10 November 2016 EMA/88527/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Movymia International non-proprietary name: teriparatide Procedure No. EMEA/H/C/004368/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 (...) authorisation to the European Medicines Agency (EMA) for Movymia, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The applicant applied for the following indication: Movymia is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated

European Medicines Agency - EPARs2017

40. Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis"

Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP "osteoporosis" 1 Translation of Chapters 1 to 6 of the final report Systematische Leitlinienrecherche und -bewertung sowie Extraktion relevanter Empfehlungen für ein DMP Osteoporose (Version 1.0; Status: 1 April 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. Extract Systematic guideline search and appraisal, as well as extraction of relevant recommendations, for a DMP “osteoporosis” 1 IQWiG Reports – V14-03 Extract of final report V14-03 Version 1.0 Guideline search and appraisal for a DMP “osteoporosis” 1 April 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Systematic guideline search and appraisal, as well as extraction of relevant

Institute for Quality and Efficiency in Healthcare (IQWiG)2017